Ron King is the CEO and Managing Board Member of Tesis. Mr. King is a seasoned health care executive with more than 25 years’ experience in the healthcare industry. Mr. King brings to Tesis the highest level of professionalism which is reflected in his management expertise as it relates to compliance, process improvement, revenue production and maximization. Mr. King has extensive experience with re-engineering and integration of workflow processes of all clinical divisions in the healthcare continuum including Genetic and infectious disease labs, with the goal to improve performance by creating proprietary processes that result in the creation of unique testing panels while concurrently reducing expenses through strategic sourcing, technology platform integration, RPA and process improvements. He has directed and managed large operations in the healthcare industry. He has extensive experience with the oversight of all clinical and administrative divisions in the industry including medical group operations and direct patient clinical divisions. He has spent many years focusing on multiple healthcare systems, with an emphasis on financial and strategic operational planning and collaboration. Mr. King holds a Master of Health Administration from Seton Hall University. Mr. King previously was a member of the ER/Trauma redesign team at Heywood Memorial in Massachusetts, an Adjunct Professor at Wachusett College, teaching on cardiovascular disease, and the Executive Director of One Care at Newport Hospital. Additionally, Mr. King has been a member of the Compliance Committee of North Country Health System in New Hampshire, the National Board of Respiratory Care and the American Association of Respiratory Care.


Todd Stottlemyre is a Co-Founder of Tesis and serves as a Managing Board Member of the Company. Mr. Stottlemyre is a former 15-year Major League Baseball pitcher and 3x world series champion. After retiring from baseball, he built and led a high performing asset management team at Merrill Lynch. He is currently a 2x bestselling author, executive coach, and speaker. He holds control positions in a variety of private companies and was one of the initial principal investors in one of the first telemedicine companies to be formed, that was successfully sold to a multi-billion-dollar national stock exchange-listed company. He is senior partner, and one of two Co-Founders of a private equity fund that holds interests in a diverse portfolio of private companies.


Dr. Shufeldt serves as a Managing Board Member of the Company. He is an emergency physician by a vocation, as well as an MBA and lawyer. He has published 10 books and two textbooks, is a licensed pilot and multidisciplinary entrepreneur who has founded and operated several successful businesses. At present, Dr. Shufeldt leads a large emergency medicine staffing and management company, Tribal Health, and continues to practice emergency medicine and health law. In 1993 Dr. Shufeldt started NextCare, which he built and staffed, and grew to over 60 urgent and primary care centers. In 2010, Dr. Shufeldt started a national virtual healthcare platform, MeMD, which grew to service patients in 50 states with more than 400 practitioners and more than 5 million subscribers. MeMD was sold to Walmart in 2021.


Dana Dittus has more than three decades of healthcare laboratory and management experience. Ms. Dittus worked recently as the administrative director for Bayonne Hospital Laboratory. Her areas of expertise include product design, clinical research, and esoteric testing across multiple healthcare settings, including hospital, long-term care, and small and large reference laboratory facilities. Ms. Dittus has participated in various inspection processes and worked with departments of health on Ebola and coronavirus testing protocols. She is deeply familiar with College of American Pathologists (CAP) accreditation standards, Joint Commission accreditation and certification, and various state departments of health regulations. Ms. Dittus holds an undergraduate degree in Allied Health from Widener University and an MBA from Holy Family University.


Dr. Jonathan Stein oversees all lab test results, supervises production, accreditation, Quality Control and QA for all the various Tesis locations. His responsibilities include overseeing the Company’s clinical research and development for new initiatives, AI, Therapeutics and new product development that are currently being considered for initiation.
For the last 15 years, Dr. Stein has been the Lab-Director and Chief Science Officer of one of the leading Labs in the Western United States. His job responsibilities included, but were not limited to, CC/QA, Scientific Review and Presentations. Assay Developments, Molecular analysis in various specialty areas including Telomer, ApoE, Prothrombin/Factor V SNPs. Biostatistical analysis, BioTek, Cell Insight, Robotics, Evaluation, Automated Lymphocyte Extraction and Multiprobe procedures. He previously served as a Research Investigator at M.D. Anderson Cancer Center. He holds a Doctoral Degree in Genetics from M.D. Anderson Cancer Center, a Ph.D. in Molecular and of Biomedical Sciences, University of Texas, MS in Population and Biomedical Sciences and B.A.(Honors) in Biochemistry. He is certified as a High Complexity and Molecular Lab Director Board Certification HCLD(ABB), Molecular(ABB) and holds a New York Dept of Health Laboratory Director Qualification, Clinical Chemistry, Endocrinology, Genetic Testing (Mol Pathology), Oncology-Soluble Tumor Markers and is fully credentialed.


As laboratory manager for Tesis Biosciences, Cydney Rios oversees all aspects of the company’s clinical diagnostic testing activities. An expert in next-generation sequencing library construction, RNA-sequencing, and primary airway epithelial culture, Ms. Rios also is laboratory director at Tesis Biosciences in Lafayette, Colorado. Prior to joining Tesis, she worked for 10 years as a lab manager at National Jewish Health in Denver, where she focused on translational genetics of lung diseases. Ms. Rios has conducted research in renal disease and hypertension at the University of Colorado in Denver and prostate cancer research in the Department of Urology at the University of Florida, where she earned a bachelor’s degree in Interdisciplinary Studies: Biology.


As Tesis Biosciences’ Chief Information Officer, Kyle Britton brings over 10 years of experience in the Healthcare IT industry. He provides strategic leadership to the company’s information technology securities, services, and solutions. Britton also oversees the IT responsibilities for the Company’s billing division, providing oversight and operational services. Previously Britton served as Desktop Support Field Supervisor for the State University of New York (SUNY) Oneonta, overseeing and collaborating with an advanced troubleshooting team and providing ongoing training to customer support specialists, where in this role, he improved performance and customer engagement while optimizing operations.


Ms. Reeves, serves as the Chief Compliance Officer for the Company. Ms. Reeves brings to Tesis a unique combination of compliance, legal and public accounting experience in healthcare. Previously she held the position of Compliance Director for Envolve Pharmacy Solutions, and prior to that was the Senior Attorney for the Agency for Health Care Administration in Florida. She has held positions in various Health Related Companies as the Compliance Director for the past two decades. She is certified in Healthcare Compliance and as a Compliance Specialist. She is a member of the Florida Bar, graduated Cum Laude on the Dean’s list and holds a B.S. in Accounting.


Dr. Divyen Patel is responsible for implementing and executing all Clinical Research Initiatives within Tesis. Dr. Patel was formally the founder and CEO of Genome Explorations, a company acquired by Tesis Biosciences in February of 2022. Dr. Patel was responsible for more than 20 years of research and development associated with that venture, which was the first commercial Genomic services provider approved by Affymetrix, which has provided gene expression, microRNA expression, genotyping, Next Generation Sequencing (NGS) and advanced data analysis services to more than 500 different academic, governmental, and commercial institutions since 2001. Dr. Patel started and managed the Genomics program at St. Jude Children’s Research Hospital and produced, among many studies, seminal work on the use of global genomics to enhance diagnosis of pediatric leukemia. Dr. Patel has been the recipient of the American Heart Association Postdoctoral Fellowship Award, The Hartwell Foundation Grant to establish and run Affymetrix Core Facility for St. Jude CRH investigators, the Memphis Business Journal’s Small business of the Year Award and Hero of the Year award. He holds a B.S. in Applied Biochemistry from Liverpool University, England, a PH.D. in Clinical Medicine and Biochemistry from the University of Leeds, England, and a Post Doctorate Degree in Pharmacology/Molecular Cor Center from the UTHSC/St Jude Children’s Research Hospital, Memphis, TN.


Brittani Hester is the Company’s Controller. She is responsible for managing the accounting operations team, overseeing the accounts payable, receivables, inventory management, payroll and sales auditing in addition to facilitating the work flow with the Company’s tax and auditing partners. She has served in the capacity of Controller for several large organizations for over 20 years, including most recently having served as the Controller for Protective Industrial Products, an international company. She is a Certified Public Accountant, in the state of Florida, holds a Master of Business Administration from State University of New York, and a Bachelor of Science in Business/Accounting from Siena College, NY.